Back to Gastroenterology
Gastroenterologyv2016Evidence-Based

Liver Decompensation Risk after Hepatectomy for Hepatocellular Carcinoma (HCC)

Predicts risk of liver decompensation after hepatectomy for hepatocellular carcinoma (HCC)

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
decompensation rate
—%
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Liver Decompensation Risk after Hepatectomy for Hepatocellular Carcinoma (HCC) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within gastroenterology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Risk stratification based on hierarchical interaction of portal hypertension, hepatectomy extent, and MELD score. Low risk: no portal hypertension + minor resection + MELD ≤9. Intermediate risk: no portal hypertension + major resection OR minor resection + (portal hypertension OR MELD >9). High risk: major resection + portal hypertension.

Clinical Pearls & Practice Notes

  • Derived from analysis of 543 patients with HCC undergoing hepatectomy
  • Portal hypertension defined as F1 esophageal varices on endoscopy OR platelets <100,000/μL with splenomegaly
  • Major hepatectomy defined as removal of ≥3 adjacent segments
  • MELD score calculated as: 3.8[ln bilirubin] + 11.2[ln INR] + 9.6[ln creatinine] + 6.4
  • Risk stratification helps guide patient selection and surgical planning
  • Higher risk patients may benefit from alternative treatments or enhanced perioperative monitoring

Evidence & Literature Citations

  1. Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, Berretta M, et al. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg. 2012 Nov;256(5):706-12; discussion 712-3. doi: 10.1097/SLA.0b013e3182724258.
  2. Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, La Barba G, et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl. 2006 Jun;12(6):966-71. doi: 10.1002/lt.20769.
  3. Santambrogio R, Kluger MD, Costa M, Belli A, Barabino M, Laurent A, et al. Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh's A cirrhosis: is clinical evidence of portal hypertension a contraindication? HPB (Oxford). 2013 Jan;15(1):78-84. doi: 10.1111/j.1477-2574.2012.00583.x.

Score Interpretation Ranges

Low Risk0 – 5 pts

Low risk of liver decompensation

Intermediate Risk20 – 35 pts

Intermediate risk of liver decompensation

High Risk55 – 65 pts

High risk of liver decompensation

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.